Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Trial sites expanded: 4 → 7 locations
- Minor: Petrelintide · Overweight or Obesity and Established Cardiovascular Disease Trial sites expanded: 3 → 11 locations
- Minor: Fixed Doses of SEP-363856 · Generalized Anxiety Disorder Trial sites expanded: 17 → 27 locations
- Minor: Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment · Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Trial sites expanded: 34 → 69 locations
- Minor: Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Trial sites expanded: 7 → 12 locations
- Minor: NX-5948 · CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) Trial sites expanded: 43 → 47 locations
- Minor: QCZ484 in Hypertensive Patients Trial sites expanded: 25 → 46 locations
- Minor: ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 14 → 19 locations
- Minor: SRP-1005 · Huntington's Disease Trial sites expanded: 4 → 8 locations
- Minor: Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Trial sites expanded: 0 → 13 locations
- Minor: Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab · Moderate to Severe HS Within the Italian Population Trial sites expanded: 16 → 22 locations
- Minor: NIS Evaluating Various Injectable and Oral Treatments · Relapsing Multiple Sclerosis Trial sites expanded: 141 → 146 locations
- Minor: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia Trial sites expanded: 42 → 49 locations
- Minor: Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery · Early-stage, Operable, Non-small Cell Lung Cancer Trial sites expanded: 42 → 45 locations
- Minor: Biomarker Targeted Stimulation for Epileptiform Events Trial sites expanded: 0 → 4 locations
- Minor: VitaSmart HOPE System: Bridge to HOPE Registry Trial sites expanded: 1 → 9 locations
- Minor: Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit Enrollment increased: 954 → 1054 participants
- Minor: Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients Enrollment increased: 300 → 400 participants
- Minor: Canadian Critical Care Comparative Effectiveness Platform Trial sites expanded: 11 → 14 locations
- Minor: Inclisiran Versus Placebo · Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Trial sites expanded: 149 → 153 locations
- Minor: Monotherapy With P2Y12 Inhibitors · Atrial fIbrillation Undergoing Drug-eluting Stent Implantation Trial sites expanded: 15 → 18 locations
- Minor: European Disease Registry on Retinopathy of Prematurity (ROP) Trial sites expanded: 59 → 79 locations
- Minor: Cardiogenic Shock Working Group Registry Trial sites expanded: 16 → 22 locations
- Minor: Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets · Overweight or Obesity Interventions modified
- Minor: Effects and Safety of RO7568282 in Early Parkinson's Disease Start date changed from estimate of Nov 10, 2026 to Nov 11, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates